Figure 1

(A) Plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. (B) Plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. (C) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. (D) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. (E) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients at week 4. (F) Dose-normalized (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in five cancer patients at week 4.